Exchange: NYSEArca·Updated 03:28 PM EDT
News
all
press releases
DFTX Stock Rallies As Psychedelic Drug Delivers Positive Anxiety Trial Results — Retail Says DT120 Could ‘Disrupt The Market’
Voyage is the company’s second successful late-stage readout for DT120, following positive results in major depressive disorder in June.
Stocktwits
More News
DFTX Stock On Track For Worst Day In 9 Months As Investors Brace For Anxiety Trial Data
Definium Therapeutics, which develops treatments for mental health conditions, faces high expectations for its late-stage Voyage study of DT120.
Stocktwits
HUBS Stock Heads Toward Worst Single-Day Fall In Over 10 Years — Wall Street Says HubSpot Is Headed To 'Penalty Box' Until Growth Improves
HubSpot's third-quarter outlook triggered a wave of analyst downgrades and price target cuts as Wall Street grew more cautious on demand.
Stocktwits
CYCU Stock Pulls Back After Nearly 500% Jump Driven By Record $54.6M Government Contract
Cycurion announced on Thursday that it had secured a 10-year, $54.6 million agreement supporting the modernization of a state Health and Human Services system.
Stocktwits
RDDT Stock Is In The Limelight Today After Massive Pre-Market Fall — GOOGL Friction Raises AI Licensing Risks, Says Wells Fargo
The selloff in Reddit shares came as investors looked past the earnings beat and focused on slowing U.S. user growth and management's commentary on its relationship with Google.
Stocktwits
How Is SpaceX (SPCX) Already the Largest of 3,372 Holdings in This $97.7 Billion Vanguard ETF?
Key PointsThe Vanguard Extended Market ETF is built around small- and mid-cap stocks -- not megacap behemoths like SpaceX...
Nasdaq News: Markets
OTLK Stock Surges After FDA Ends Decade-Long Wait For Ophthalmic Bevacizumab
LYTENAVA is now the first and only FDA-approved version of the drug bevacizumab specifically made for injection into the eye to treat wet age-related macular degeneration.
Stocktwits
FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials
The clearance allows the company to begin an early-stage basket trial in multiple autoimmune diseases later this year.
Stocktwits
ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal
The payment gives Aligos non-dilutive funding as it advances its pipeline of treatments for liver and viral diseases.
Stocktwits
UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval
Unicycive Therapeutics said on Tuesday that the U.S. Food and Drug Administration has again refused to approve its drug oxylanthanum carbonate.
Stocktwits

Advertisement|Remove ads.